Investing
Dryships, Agile Therapeutics in Thursday's 52-Week Low Club
Published:
Last Updated:
January 5, 2017: Here are four stocks trading with relatively heavy volume among 20 equities making new 52-week lows in Thursday’s session. On the NYSE, decliners led advancers by about 9 to 7 and on the Nasdaq decliners led advancers by about 3 to 2.
DryShips Inc. (NASDAQ: DRYS) dropped about 14.6% on Thursday to post a new 52-week low of $2.98 against a 52-week high of $278.40 and a Wednesday close of $3.49. Volume of about 17 million was more than double the daily average of around 7.8 million. The dry bulk shipper announced this morning that it plans to buy up to 4 very-large gas carriers at a cost of $83.5 million each.
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) dropped 9% on Thursday to post a new 52-week low of $3.72 after closing at $4.09 on Wednesday. Volume was more than double the daily average of about 3 million shares. The company had no specific news Thursday.
Express Inc. (NYSE: EXPR) dropped about 6.8% Thursday to post a new 52-week low of $10.07 after closing Wednesday at $10.80. The 52-week high is $21.57. Volume of around 2.7 million was about 15% more than the daily average of around 2.3 million shares traded. The company had no specific news.
Aeterna Zentaris Inc. (NASDAQ: AEZS) dropped about 36% on Thursday to post a new 52-week low of $2.35 after closing at $3.65 on Wednesday. The stock’s 52-week high is $5.59. Volume was about 5 times the daily average of around 430,000 shares. The company said late Wednesday that a clinical trial had failed.
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.